| domain | established finding | quantitative/patient evidence | suggested ontology terms | evidence level/limitations |
|---|---|---|---|---|
| Identity / nosology | The target condition maps best to **MIPEP-related combined oxidative phosphorylation deficiency 31 (COXPD31)**, also described clinically as **cardiomyopathy-hypotonia-lactic acidosis syndrome** and **Eldomery-Sutton syndrome**; OMIM **617228** for the disorder and MIPEP gene OMIM **602241**. Disease-level knowledge is derived from aggregated case reports/reviews rather than EHR-scale datasets. | Landmark discovery study reported **4 unrelated probands** with a shared syndromic presentation; later reviews consistently refer to this as COXPD31. (pqac-00000011, pqac-00000007, pqac-00000006) | MONDO/Orphanet/ICD/MeSH mappings: **database verification needed**; NCIT: mitochondrial disease/cardiomyopathy terms may be mappable but need verification | **Primary human evidence** plus expert reviews. Limitation: ultra-rare disorder with very small published cohort; nomenclature varies across papers. |
| Gene / inheritance | Cause is **biallelic pathogenic variation in MIPEP** encoding mitochondrial intermediate peptidase (MIP). Inheritance is **autosomal recessive**. | Discovery cohort: 4/4 had **biallelic** MIPEP variants (compound heterozygous, homozygous, or SNV+deletion). Reviews explicitly label COXPD31 as a **severe autosomal recessive disorder**. (pqac-00000011, pqac-00000007, pqac-00000001) | HGNC: **MIPEP**; GO CC/BP suggestions: **mitochondrial matrix**, **protein maturation**, **mitochondrial protein processing**; MONDO inheritance term/HP inheritance term: database verification needed | **Strong primary genetic evidence**. Limitations: penetrance, carrier frequency, founder effects, and population prevalence not established. |
| Core phenotypes | Core syndrome includes **left ventricular non-compaction (LVNC)/cardiomyopathy, severe hypotonia, developmental delay, seizures, cataracts**, with lactic acidemia/acidosis in several patients and broader multisystem disease. | In discovery cohort, shared predominant features were **LVNC, developmental delay, seizures, hypotonia**; **3/4** had infantile/childhood death. Specific subsets included cataract (patient 2), microcephaly and basal ganglia MRI abnormalities (patient 3), congenital hyperinsulinism and severe neonatal lactic acidosis (patient 4), metabolic myopathy on biopsy (patients 1,2,4). (pqac-00000011, pqac-00000009, pqac-00000010, pqac-00000012, pqac-00000015, pqac-00000016) | HPO suggestions needing verification: cardiomyopathy/LV noncompaction, hypotonia, developmental delay, seizures, cataract, lactic acidosis, failure to thrive, microcephaly, hypertrophic cardiomyopathy, dilated cardiomyopathy, facial dysmorphism | **Primary human case evidence**. Limitations: frequencies beyond the first 4 cases are unknown; phenotype appears broader than original syndrome label. |
| Discovery variants | Reported pathogenic discovery variants included missense, nonsense, and CNV alleles affecting MIPEP. | Patient 1: **c.1745T>G p.L582R** + **c.212T>A p.L71Q**; Patient 2: **c.916C>T p.L306F** + **c.1804G>T p.E602\***; Patient 3: **c.1027A>G p.K343E** homozygous; Patient 4: **c.1534C>G p.H512D** + maternal **1.4-Mb 13q12.12 deletion** including MIPEP. ExAC frequencies reported for p.L306F **8.2×10^-6** and p.H512D **3.2×10^-5**; other four variants were novel at publication. (pqac-00000011, pqac-00000010, pqac-00000013, pqac-00000024) | Sequence Ontology suggestions: missense variant, stop gained, copy number loss; ClinVar/ACMG status: current database verification needed | **Primary genetic evidence** with segregation/confirmation. Limitation: current ClinVar classifications and modern population frequencies require live database check. |
| Cardiac phenotype | Cardiac disease is central and variable, including **LVNC**, **dilated cardiomyopathy**, **hypertrophic cardiomyopathy**, and conduction abnormalities. | Patient 1: LVNC + **Wolff-Parkinson-White**; Patient 2: **LVNC with dilated cardiomyopathy**; Patient 3: left ventricular hypertrophy without outflow obstruction; Patient 4: **severe biventricular hypertrophic cardiomyopathy** with non-compaction and heart failure. Reviews summarize LVNC, DCM, and HCM within the syndrome. (pqac-00000013, pqac-00000010, pqac-00000012, pqac-00000006, pqac-00000007) | UBERON: heart/left ventricle; HPO suggestions: LV noncompaction, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmia, heart failure | **Primary case evidence** plus reviews. Limitation: no formal natural-history series defining cardiac progression. |
| Biochemical / pathology findings | Disease behaves as a **mitochondrial proteostasis / OXPHOS disorder** with metabolic acidosis, lactate elevation, abnormal ETC studies, and muscle/cardiac mitochondrial pathology. | Reported values/examples: patient 1 lactate **3.2 mmol/L** with anion gap **25**; patient 3 lactate **4.4** and **11.1 mmol/L** at admissions; patient 4 lactate **8.9–10.4 mmol/L**. Muscle/cardiac pathology showed **lipid droplets, glycogen deposition, mitochondrial proliferation/pleomorphism, enlarged mitochondria with bloated vesicular cristae**; mild reductions in multiple respiratory complexes reported in some tissues. (pqac-00000013, pqac-00000010, pqac-00000012, pqac-00000008) | CHEBI suggestions: lactate, pyruvate; HPO suggestions: lactic acidosis, increased serum alanine, mitochondrial myopathy, abnormal mitochondrial morphology | **Primary human biochemical/pathology evidence**. Limitation: ETC abnormalities were variable and not uniformly quantified across patients/tissues. |
| Mechanism / pathophysiology | MIPEP/MIP performs **secondary cleavage of imported mitochondrial preproteins** after MPP. Loss of function causes defective maturation/stability of a subset of matrix proteins, accumulation of processing intermediates, impaired respiratory-chain function, and bioenergetic failure in energy-demanding tissues. | Background: ~**70%** of mitochondrial preproteins are nuclear-encoded/imported; about **25%** of preproteins require a second cleavage by MIP/Oct1 or XPNPEP3/Icp55. Yeast homolog experiments showed patient-corresponding mutants caused **loss of localization** (L83Q corresponding to human L71Q) or **markedly reduced protease activity** (L339F/K376E corresponding to human L306F/K343E), with accumulation of substrates including **Sdh4, Rip1, Cox4, Mdh1, Mrp21, Prx1, Mdj1**, and respiratory-growth defects. (pqac-00000011, pqac-00000008, pqac-00000012, pqac-00000007, pqac-00000014) | GO BP suggestions: protein targeting to mitochondrion, mitochondrial protein processing, oxidative phosphorylation, respiratory electron transport chain, mitochondrial protein stabilization; GO CC: mitochondrial matrix, inner mitochondrial membrane; CL suggestions: cardiomyocyte, skeletal muscle cell, neuron (verification needed) | **Strong mechanistic evidence** from functional modeling and established mitochondrial biology. Limitation: direct human cell multi-omics and tissue-specific mechanistic studies remain sparse. |
| Diagnosis | Best-supported diagnostic approach is **genomic testing** in the setting of infantile mitochondrial disease plus targeted biochemical/cardiac workup. | Discovery used **whole-exome sequencing**, Sanger confirmation, and array CGH for the deletion case. Reviews/guidelines for primary mitochondrial disease support **WES/NGS as first-line or early testing**, with adjunctive lactate/pyruvate, amino acids, urine organic acids, ECG/echocardiography, neuroimaging, and muscle biopsy where needed. (pqac-00000011, pqac-00000009, pqac-00000020, pqac-00000017, pqac-00000021) | NCIT/LOINC/HPO mappings for WES, echocardiogram, ECG, lactic acidosis, muscle biopsy: database verification needed | **Primary disease-specific evidence for WES**, broader **expert-consensus extrapolation** for surveillance/diagnostic workflow. Limitation: no MIPEP-specific diagnostic criteria published. |
| Treatment / management | **No MIPEP-specific disease-modifying therapy** has been established. Current care is **supportive and complication-directed**, extrapolated from primary mitochondrial disease standards and pediatric cardiology/epilepsy care. | Real-world interventions in the cohort included cataract surgery, ventilatory support, metabolic workup, transplant listing, and **Berlin assist device** in patient 2. Broader mitochondrial guidance supports avoiding fasting, optimizing nutrition/hydration, prompt treatment of intercurrent illness, annual or baseline cardiac surveillance, seizure management with standard antiseizure drugs (expert preference often levetiracetam/benzodiazepines), rehabilitation, and individualized supplement use only when gene-specific evidence exists. No relevant MIPEP/COXPD31 clinical trial was identified in the trial searches. (pqac-00000010, pqac-00000012, pqac-00000017, pqac-00000018, pqac-00000019, pqac-00000020, pqac-00000021, pqac-00000022) | NCIT suggestions needing verification: supportive care, physical therapy, occupational therapy, anticonvulsant therapy, cardiac assist device, heart transplantation evaluation | **Disease-specific care evidence is weak**; mainly **expert-consensus extrapolation** from broader mitochondrial disease. Limitation: no controlled treatment data and no MIPEP-targeted therapy/trial found. |
| Prognosis / outcomes | Prognosis appears **severe, often infantile-onset and frequently fatal**, driven largely by cardiomyopathy and multisystem decompensation. | In the original 4-patient cohort, **3/4 (75%) died within the first 3 years of life**; one child was alive at **4.5 years** with ongoing neurologic morbidity. Deaths occurred in infancy/early childhood, including patient 3 at **11 months**, patient 4 at **19 days**, and patient 2 at **2 years**. (pqac-00000008, pqac-00000010, pqac-00000012, pqac-00000015) | HPO suggestions: infantile onset, early death, global developmental delay, progressive neurologic deterioration | **Primary outcome evidence** but from a tiny cohort. Limitation: life expectancy, stage-specific survival, and prognostic biomarkers are not yet defined. |
| Epidemiology / population | The disease is **ultra-rare**; no disease-specific prevalence, incidence, sex ratio, or carrier frequency estimates were identified. | Published evidence located only a handful of cases/references; broader mitochondrial disease prevalence data do not allow reliable COXPD31-specific estimates. (pqac-00000011, pqac-00000004, pqac-00000021) | MONDO/Orphanet prevalence fields: database verification needed | **Evidence gap**. Important to state as unknown rather than infer from primary mitochondrial disease generally. |
| Environmental / protective factors | No validated environmental causes, infectious triggers, gene-environment interactions, or protective factors are known for COXPD31 specifically. Clinical stressors likely worsen decompensation, as in other mitochondrial diseases. | Broader mitochondrial standards note vulnerability during intercurrent illness and metabolic stress, but this is extrapolated and not MIPEP-specific. (pqac-00000017, pqac-00000021) | HPO/ExO/ENVO mappings: database verification needed | **Extrapolated expert opinion only**; no disease-specific studies. |
| Model organism | Functional disease modeling has been demonstrated in **Saccharomyces cerevisiae** using **Oct1**, the MIPEP ortholog. | Yeast mutants corresponding to human variants showed absent mitochondrial localization (L83Q/human L71Q), reduced protease activity (L339F and K376E corresponding to human L306F and K343E), accumulation of non-processed substrates, and failure of respiratory growth at high temperature. (pqac-00000011, pqac-00000012, pqac-00000008) | NCBI Taxon suggestion: *S. cerevisiae* (verification needed); GO: mitochondrial protein processing, respiratory growth | **Direct functional evidence**. Limitation: yeast does not model human organ-level phenotypes such as LVNC, seizures, or cataracts. |


*Table: This table summarizes the strongest available evidence for MIPEP-related combined oxidative phosphorylation deficiency 31, including identity, inheritance, phenotypes, variants, mechanism, diagnosis, treatment, prognosis, and model systems. It emphasizes what is established from primary reports versus what still requires database verification or extrapolation from broader mitochondrial disease guidance.*